January 26, 2000

Prognostic Value of Pololike Kinase Expression in Melanomas

Author Affiliations

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor


Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000

JAMA. 2000;283(4):479-480. doi:10.1001/jama.283.4.475

To the Editor: The incidence of cutaneous malignant melanoma is increasing more rapidly than that of any other cancer among the white population.1 Melanomas cause more than 75% of all skin cancer deaths.2 Because the Breslow3 thickness of a primary tumor is related to its metastatic potential, this factor often guides surgical management. However, some thin melanomas can metastasize despite a favorable Breslow thickness.4 Therefore, better prognostic factors are required for definition of malignant potential.

First Page Preview View Large
First page PDF preview
First page PDF preview